Open label study of ONTAK® in previously treated cutaneous T-cell lymphoma patients

Journal of Drugs in Dermatology, Jan-Feb, 2004

Sponsored by Ligand Pharmaceuticals

The purpose of this study is to provide an opportunity for patients who exhibit progressive disease while receiving placebo on the companion 93-04-11 study to receive ONTAK. It is also designed to determine the effectiveness of ONTAK in CTCL patients whose tumors do not express CD25.

Condition                    Treatment or Intervention  Phase

Lymphoma, T-Cell, Cutaneous  Drug: ONTAK[R]             Phase IV
Mycosis Fungoides
Sezary Syndrome

Study ID Number 93-04-14

NLM Identifier NCT00051012